Ollin Biosciences, Inc.
PrivateLast Round
Series A
Sep 17, 2025
Est. Valuation
$500M
Total Funding Raised
$100M
Company Overview
Ollin Biosciences, Inc. is a biopharmaceutical company that develops therapies for vision-threatening ophthalmic diseases such as wet age-related macular degeneration and diabetic macular edema.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ollin Biosciences, Inc. Comps
Public and private peers based on sector, stage, and business model.
Ollin Biosciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 17, 2025 |
Ollin Biosciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Monograph Capital | Series A |
| ARCH Venture Partners | Series A |
| Mubadala Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2026
Drug candidate OLN324 will advance to Phase III trials.
- Jan 9, 2026
Partnered with Innovent Biologics for OLN324 development.
Ollin Biosciences, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ollin Biosciences, Inc.'s valuation, stock price, and market status.
